Pricing Log in Create free account

CASI Pharmaceuticals Inc. (CASIF) vs TScan Therapeutics, Inc. (TCRX)

CASI Pharmaceuticals Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and TScan Therapeutics, Inc. are of similar size ($12.4M and $12.3M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −27.4%. CASI Pharmaceuticals Inc. has the higher net margin (−232.0% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 17 metrics below, CASI Pharmaceuticals Inc. leads on 9 and TScan Therapeutics, Inc. on 8.

Valuation

Metric CASIF TCRX Biotechnology median
P/E n/m n/m 10.60
P/S 0.10 3.29 9.40
P/B n/m 0.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.37 0.66
EV/Sales 1.80 (6.19) 9.02
Earnings yield (2,455.91%) (505.56%) (32.88%)
Free cash flow yield (3,455.46%) (506.23%) (23.13%)

Profitability

Metric CASIF TCRX Biotechnology median
Gross margin 48.65% 100.00% 68.51%
Operating margin (206.87%) (1,695.15%) 0.00%
Net margin (232.03%) (1,655.35%) 0.00%
Free cash flow margin (340.20%) (1,665.18%) 0.00%
Return on equity 0.00% (95.80%) (51.96%)
Return on assets 0.00% (50.09%) (46.06%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric CASIF TCRX Biotechnology median
Revenue growth (TTM) (27.42%) 2.15% 6.76%
EPS growth (last fiscal year) (1.17%) 12.28% 29.88%
Revenue growth, 5-year CAGR 6.47% 56.92% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CASIF TCRX Biotechnology median
Debt to equity (0.34) 0.47 0.00
Current ratio 0.15 3.37 4.97
Net debt to EBITDA (0.43) 0.90 1.01

Dividend

Metric CASIF TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CASIF TCRX Biotechnology median
Market cap 12.39m 12.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack